Angelalign (06699) has announced that its board of directors resolved on September 11, 2026, to award a total of 1,563,900 restricted share units to 16 grantees under the post-IPO restricted share unit plan.
Among the awards, 1,255,800 restricted share units were granted to three executive directors, namely Mr. Feng, the executive director and board chairman, Mr. Hu, the executive director, chief executive officer, and chief technology officer, and Mr. Huang, the executive director and president of global business (excluding mainland China), in the form of a three-year restricted share unit grant. This one-time, three-year retrospective award is designed to recognize their past contributions and achieved performance.
Additionally, 308,126 restricted share units were granted to 13 other employees of the company, classified as other restricted share unit grants, which together with the three-year restricted share unit grant form the total restricted share unit awards.
The three-year restricted share unit grant is conditional upon approval by independent shareholders at an extraordinary general meeting and acceptance by the selected director grantees.
The group delivered robust results in the first half of 2026, with revenue and net profit increasing by 42.9% and 79.6%, respectively, compared to the same period in 2025. Following the momentum built since the launch of its first three-year globalization plan in 2022, the group's global business (excluding mainland China) reached major milestones during the reporting period, with case numbers and revenue each accounting for more than half of the group's total clear aligner cases and revenue, while achieving profitability ahead of schedule.
The board believes the speed and scale of the group's globalization transformation are particularly notable. This is not merely geographic expansion but requires fundamental changes in personnel, capabilities, culture, and operating model to become a more globally oriented enterprise. Transitioning from a domestic-focused company to a global one involves winning the trust of new customers, adapting to diverse clinical practices and market environments, attracting and empowering international talent, and navigating complex regulatory and operational requirements across multiple jurisdictions.
The restricted share unit awards aim to recognize the contributions of the group's management team to business development and globalization. In particular, when considering the three-year restricted share unit grant to selected director grantees, the board and the remuneration committee noted that these directors played pivotal roles in formulating and executing the group's globalization strategy and business development initiatives yet had not previously received any equity incentives from the company. Therefore, the three-year restricted share unit grant serves as a one-time, three-year retrospective reward that acknowledges the past contributions of the selected director grantees and was only determined after the group achieved and exceeded the key milestone targets set under its initial three-year globalization plan.